CLI Ventures — 2016 Investments
2 investments dated 2016 · listed companies and verified rows first · show all
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Co-investorsAvoro Capital AdvisorsKhosla VenturesNew Enterprise Associates (NEA)SR One Capital ManagementVersant VenturesWellington Management+2 more
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
BiotechMedical DevicesPalo Alto, US
Xiaoling Charlene Liao(Executive Officer, Director)Charlene Liao(Founder)in
BoardGuo-Liang Yu(Director)Liqun Luo(Director)
Co-investorsNorthern Light Venture CapitalShangBay Capital LLCStartXVivo CapitalTriWise Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.












